GlassScriptPhysician profile
Saad Muhammad Amin
NPI 1437501202
$1,551.11
in general payments reported to CMS, 2019-2025
21 companies · $972 in 2025
The $972 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.27 · 2020: $53.34 · 2021: $89.06 · 2022: $159 · 2023: $50.86 · 2024: $196 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $203.58 | 2020-2023 | Xarelto |
| Pfizer INC. | $176.66 | 2025 | |
| Shockwave Medical, INC | $146.71 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.42 | 2020-2025 | Lifevest |
| Verona Pharma, INC. | $84.41 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $81.73 | 2025 | |
| Novartis Pharmaceuticals Corporation | $77.97 | 2021-2022 | |
| Grifols USA, LLC | $65.95 | 2024-2025 | Prolastin-C Liquid |
| Heartflow, INC. | $65.89 | 2025 | |
| Alnylam Pharmaceuticals INC. | $63.57 | 2025 | Onpattro |
| La Jolla Pharmaceutical Company | $59.58 | 2025 | Giapreza |
| United Therapeutics Corporation | $55.22 | 2024-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $54.64 | 2025 | Winrevair, Keytruda |
| Abiomed | $54.41 | 2025 | |
| Viatris Specialty LLC | $51.65 | 2025 | Yupelri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $48.98 | 2019-2025 | Eliquis |
| Stryker Corporation | $48.88 | 2025 | Flowtriever |
| Astrazeneca Pharmaceuticals LP | $48.40 | 2019-2025 | Wainua, Farxiga |
| Vital Connect, INC | $26.01 | 2025 | Vitalpatch Rtm |
| Edwards Lifesciences Corporation | $25.49 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Philips North America LLC | $14.96 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Muhammad Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.